Skip to content
OpenCapital
Get started

Opus Genetics IRD Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
——
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
——

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's increase (decrease) in accounts receivable?
Opus Genetics (IRD) reported increase (decrease) in accounts receivable of -$264K in Q1 2026.
How has Opus Genetics's increase (decrease) in accounts receivable changed year-over-year?
Opus Genetics's increase (decrease) in accounts receivable increased by 45.3% year-over-year, from -$483K to -$264K.
What does increase (decrease) in accounts receivable mean?
The net change in amounts owed to the company by customers for goods or services delivered on credit. A significant increase may indicate rising sales, but could also signal potential collection delays or credit risk.